124 results about "Fatty Depositions" patented technology

The invention discloses a BMI-driven 3D organ obesity visualization system based on multi-modal fusion, and relates to the technical field of medical science, the system comprises a BMI-driven prediction model, the BMI-driven prediction model is used for establishing a quantitative mapping model of a BMI index and three-dimensional organ fat deposition, and the quantitative mapping model is used for establishing a BMI index and three-dimensional organ fat deposition. The BMI driving type prediction model comprises a multi-modal data fusion unit, a model mapping unit and a residual compensation unit. By installing the BMI driving type prediction model, precise nonlinear mapping of the BMI index and organ fat deposition is achieved, the problem that traditional single-mode prediction is large in deviation is solved, and organ fat volume prediction precision and individual difference adaptability are improved.

The application belongs to the field of intestinal microbiology, and discloses a new mucinophilic Akkermansia with improved obesity and glycolipid metabolism, wherein the mucinophilic Akkermansia strain is Akk-101 and AMY001. The preservation number of Akk-101 is CGMCC No. 40786, and the preservation number of AMY001 is CGMCC No. 46141. The Akk-101 and AMY001 strains in the application are different from standard strains in nucleotide consistency and physiological and biochemical indexes, have better acid-base tolerance and colonization capacity than the standard strains, can more effectively inhibit the accumulation of liver cell lipids, reduce the fat deposition in nematodes, and have the effects of weight loss and improvement of glycolipid metabolism, so that related products can be effectively developed based on the strains.

The invention belongs to the field of medicines, and discloses application of pyroglutamic acid in preparation of products for inhibiting fat deposition. The invention has the following advantages: 1, obesity induced by high fat diet is prevented; 2, pyroglutamic acid is a natural amino acid derivative, widely exists in animal and plant bodies, and has good biological safety; meanwhile, the invention further discloses a product for inhibiting fat deposition.

The invention discloses a pig feed for increasing intramuscular fat of pork and a preparation method thereof, and belongs to the technical field of pig feeds. The pig feed comprises the following components in parts by weight: 100-120 parts of a basal feed, 3-4 parts of a compound enzyme agent, 5-7 parts of a probiotic compound bacterial agent, 1-3 parts of a vitamin additive, 20-30 parts of rice bran, 10-15 parts of a fat supplement and 3-6 parts of a functional additive. By adding various functional regulators beneficial to increase of fat in pork muscles, deposition of fat in the pork muscles is improved through various ways, and the corn, the soybean cakes and the wheat germs can provide high energy, so that fat deposition can be increased in the growth process of the pork; fat supplements rich in omega-3 fatty acid, such as flaxseed oil or fish oil, are added into the feed, so that the flavor of meat and the proportion of healthy fat can be improved, and the deposition and quality of intramuscular fat are influenced.

The invention belongs to the field of intestinal microbiology, and discloses a novel ackermania muciniphila capable of improving obesity and glycolipid metabolism, and the ackermania muciniphila strains are Akk-101 and AMY001. The preservation number of the Akk-101 is CGMCC (China General Microbiological Culture Collection Center) No. 40786, and the preservation number of the AMY001 is CGMCC No. 46141. The Akk-101 and AMY001 strains are different from standard strains in nucleotide consistency and physiological and biochemical indexes, have acid-base tolerance and colonization ability superior to those of the standard strains, and have the effects of more effectively inhibiting lipid accumulation of liver cells, reducing fat deposition in nematode bodies, losing weight and improving glycolipid metabolism. Therefore, related products can be effectively developed based on the strain.

The invention discloses application of an overexpressed carp lpla gene in regulation and control of expression of cyprinid fish tissue-related genes, and relates to the field of gene engineering, in particular to application of the overexpressed carp lpla gene in regulation and control of cyprinid fish tissue-related genes. The overexpressed carp lpla gene is applied to regulation and control of contents of lipid indexes of total cholesterol TC and triglyceride TG of different tissues of cyprinid fishes. The invention further discloses application of the overexpressed carp lpla gene in regulation and control of fat marker genes lpla, ppar gamma, Fabp3, fast and acaca of livers and muscle tissues of cyprinid fishes. The invention further discloses application of the overexpressed carp lpla gene in regulating and controlling the relative expression quantity of carp liver cell fat metabolism related genes lpla, ppar gamma, Fabp3, fast, acaca, hsl and pnpla2. The overexpressed carp lpla gene can regulate and control lipid deposition in different tissues in zebra fish, and a research model is provided for lpla to regulate and control fat deposition and differentiation. According to the overexpressed carp lpla gene disclosed by the invention, lpla high-expression carp hepatocytes are obtained through a liposome transfection technology, so that fat key gene expression in the carp hepatocytes is changed.

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The invention relates to the technical field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for treating alcoholic liver injury, a preparation and application thereof, the optimal medicine ratio is determined, the traditional Chinese medicine composition is dendrobium officinale liver protection soup, and the active ingredient raw materials of the traditional Chinese medicine composition comprise the following raw materials in parts by weight: 5-15 parts of dendrobium officinale, 6-10 parts of turmeric, 10-20 parts of radix puerariae, 6-12 parts of medicated leaven and 2-6 parts of amomum cardamomum. The dendrobium huoshanense liver protection decoction can remarkably reduce the levels of ALT, AST and TG in mouse serum, reduce the content of MDA in the liver and the levels of IL-1beta, IL-6 and TNF-alpha, improve the SOD level, relieve fat deposition in the mouse liver, relieve pathological damage to the mouse liver and relieve the oxidative stress level and the inflammatory factor level, and has a good protection effect on the liver with alcoholic liver damage.

The invention discloses a method for establishing a co-culture system of porcine skeletal muscle satellite cells (PSCs) and porcine precursor fat cells (ADSCs). The method comprises the following steps: selecting a PSCs and ADSCs co-culture proliferation culture medium and a co-culture differentiation culture medium, and establishing an optimal cell co-culture ratio. According to the optimal co-culture proliferation and differentiation culture medium for the PSCs and the ADSCs and the established co-culture proportion, mass proliferation and efficient differentiation of cells can be promoted, the influence of addition of fat cells with different concentrations on muscle cell differentiation can be researched, fat deposition in co-culture is regulated by regulating the proportion of the fat cells, and the differentiation of the muscle cells is promoted. And an earlier-stage foundation is provided for explaining a signal mechanism theoretical basis between cells under growth and development conditions of muscle and adipose tissues and exploring cell culture meat in a later stage.

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to fermented lactobacillus mucus with an anti-aging function and application of the fermented lactobacillus mucus. The strain is preserved in Guangdong Microbial Culture Collection Center on August 27, 2025, and the preservation number is GDMCC No: 66877. Experimental results show that the bacterium has excellent oxidation resistance, can relieve oxidative damage, delay senescence and inhibit senescence-related gene expression, shows the capabilities of improving memory reproduction capability decline caused by senescence, improving body anti-inflammatory capability and improving intestinal flora imbalance induced by senescence, and can regulate fat factor level and improve energy metabolism, so that the function of resisting senescence is achieved. And the polypeptide shows the potential of resisting fat deposition and protecting liver functions. Therefore, the strain can be used for developing products with multiple beneficial functions of delaying senescence, contributing to resisting oxidation, assisting in improving memory, contributing to regulating intestinal flora and the like, has the advantages of high safety, strong gastrointestinal tract tolerance and good colonization ability, and has a very good application value.

This invention relates to the field of biomedical technology, specifically to the application of 6-ketolithocholic acid in the preparation of drugs that reduce fat deposition. The 6-ketolithocholic acid in this invention inhibits the accumulation of lipid droplets in adipocytes and suppresses gene expression in the PPARγ pathway involved in lipid synthesis, thereby achieving the function of reducing fat deposition. The structural formula of the 6-ketolithocholic acid is: [Insert structural formula here].

The invention relates to the technical field of animal model construction, and discloses a non-alcoholic steatohepatitis model and a construction method and application thereof. The construction method comprises the following steps: performing stable overexpression on an AKT gene in the liver of a mouse by adopting a high-pressure caudal vein transfection technology, and feeding the mouse by adopting a high-fat feed. The non-alcoholic steatohepatitis model constructed by the construction method provided by the invention has the characteristics of liver inflammatory cell infiltration, liver fat deposition, insulin resistance, dyslipidemia and the like, has high clinical pathology similarity with NASH, has a remarkable steatohepatitis phenotype, can be used for researching the occurrence and development mechanism of NASH and evaluating the treatment effect of drugs, and has a wide application prospect. The method is of great significance to prevention and treatment of generation and development of NASH; meanwhile, the construction method is simple to operate, does not need transgenic animals, is short in feeding period, low in cost and high in efficiency, can effectively shorten the establishment period of the non-alcoholic steatohepatitis animal model, and has a good application prospect.

The invention relates to a feed for procambarus clarkii. The feed comprises the following components: animal protein, vegetable protein, grease, an energy feed, an additive, a filler and an adhesive. The feed is simple in formula and rich in nutritional ingredients, and can meet the growth requirement of the procambarus clarkia, improve the muscle quality of the procambarus clarkia, reduce muscle fat deposition, improve the antioxidant capacity of the body, improve the intestinal tissue structure, improve the digestive enzyme activity of the intestinal tract, reduce the abundance of harmful bacteria in the intestinal tract and improve the immunity of the procambarus clarkia. The growth performance, the muscle quality and the intestinal health of the procambarus clarkii are effectively improved.

The invention belongs to the technical field of poultry breeding, and discloses siRNA for targeted inhibition of chicken PLCD4 gene expression and application thereof. The siRNA comprises PLCD4-853, PLCD4-528 and PLCD4-1870, and the siRNA comprises PLCD4-853, the siRNA can inhibit the expression of the chicken PLCD4 gene in a targeted manner, after the siRNA is transferred into chicken primary subcutaneous fat cells, the expression of the chicken PLCD4 gene can be effectively reduced, the inhibition efficiency reaches 50% or above, and the knock-down efficiency is very high; the siRNA identifies the gene function by specifically knocking down the expression of the chicken PLCD4 gene in vitro, can be used as a molecular marker to be applied to genetic breeding of subcutaneous fat deposition of high-quality broilers, and has great economic value and scientific research value.

The invention provides an organoid culture medium, an organoid culture method and application of the organoid culture medium, the organoid culture medium comprises a first-stage culture medium, the first-stage culture medium comprises a first-stage basic culture medium and first-stage addition factors, and the first-stage addition factors comprise N-acetylcysteine, nicotinamide, a ROCK inhibitor, Noggin, R-spondin, EGF, HGF, Gastrin, FGF10, Blebbistatin, Forskolin, A83-01, LDN193189, DAPT, TGF-alpha and UDAC. By using the organoid culture medium, the liver organoid and the fatty liver organoid can be effectively obtained, and the obtained fatty liver organoid has obvious fat deposition, is sensitive to fatty liver treatment drugs, highly restores the physiological status when human body fatty liver diseases occur, and has high application value.

The application belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to a fermented Lactobacillus muci genus with a function of delaying aging and application thereof. The bacterium was preserved in the Guangdong Microbial Culture Collection Center on August 27, 2025, and the preservation number is GDMCC No: 66877. Experimental results show that the bacterium has excellent antioxidant performance, can relieve oxidative damage, delay aging, inhibit the expression of aging-related genes, and has the ability to improve the memory reproduction ability decline caused by aging, improve the body's anti-inflammatory ability, improve the intestinal flora imbalance induced by aging, and can regulate the level of fat factors, improve energy metabolism, and has the potential of anti-fat deposition and protection of liver function. Therefore, the bacterium can be used to develop products with multiple beneficial functions such as delaying aging, helping to antioxidant, auxiliary improving memory, helping to regulate intestinal flora, and has the advantages of high safety, strong gastrointestinal tolerance, good colonization ability, and has good application value.

The present invention relates to the field of animal breeding technology, and in particular to the use of porcine deoxycholic acid in reducing animal fat deposition. The present invention uses UCP1 genetically modified pigs with a low-fat phenotype to conduct targeted metabolic analysis in feces, and discovers and identifies a pig intestinal endogenous metabolite that can reduce fat deposition, porcine deoxycholic acid, whose chemical formula is C 24 H 40 O4. The present invention finds that the content of swine deoxycholic acid can indicate the fat deposition ability of pigs, and oral administration of swine deoxycholic acid to mice can significantly reduce the fat deposition of mice. The swine deoxycholic acid provided by the present invention has the effect of reducing fat deposition, and can be developed as a feed additive for reducing pig fat deposition in the future. At the same time, it can be applied to the research and development of drugs for reducing human obesity, providing a scientific basis for the treatment of human obesity and other diseases.

The invention discloses a composition for dispelling effects of alcohol and protecting liver as well as a preparation method and application thereof. The composition is prepared from the following raw material medicines: 30-50 parts of oyster peptide, 50-100 parts of radix puerariae, 50-100 parts of hovenia dulcis thunb, 20-30 parts of chrysanthemum, 20-30 parts of endothelium corneum gigeriae galli, 20-30 parts of malt, 20-30 parts of pericarpium citri reticulatae, 20-30 parts of liquorice, 20-30 parts of fructus lycii, 10-20 parts of red dates, 10-20 parts of American ginseng and 10-20 parts of corn oligopeptide. Pharmacodynamic tests show that the composition can significantly reduce drunkenness time, improve activity of ethanol-related metabolic enzymes, reduce levels of serum ALT, AST and ALP induced by acute alcoholic liver injury, enhance expressions of various antioxidant systems in liver tissues, significantly inhibit secretion level of inflammatory factors in serum, and improve liver injury resistance. Meanwhile, hepatic lesions and fat deposition are relieved at a histological level, so that the composition disclosed by the invention has obvious functions of dispelling the effects of alcohol and protecting the liver through scientific proportioning and synergistic interaction of the raw materials.

Systems and methods for treating cellulite including an apparatus that applies or a method involving separating septa to eliminate or reduce the appearance of cellulite. In one approach, an interventional tool is placed between tissue layers to engage and treat septa connecting tissue layers between which fat deposits are contained.

This invention discloses anti-leptin monoclonal antibodies and their applications, relating to the field of biotechnology. This invention develops anti-leptin monoclonal antibodies 2A122H7 and 6B62E3, which can effectively recognize leptin. The ELISA kits prepared using these monoclonal antibodies 2A122H7 and 6B62E3 include indirect ELISA and double-antibody sandwich ELISA kits, exhibiting high specificity and sensitivity for the tested samples, and are convenient, efficient, and cost-effective. This invention provides effective technical support for advancing research on the regulatory mechanisms of economic traits such as feed intake, fat deposition, and reproduction in poultry.

The application provides a molecular marker related to tail fat deposition of sheep, a detection method and application thereof. Through PCR amplification and sequence analysis of rBAT (SLC3A1) gene of the sheep, a C / T polymorphic site at the 689th position of the amplified fragment is found, further, the polymorphic site of 1286 Hu sheep is detected by using KASPar primers, a least square model is established, and correlation analysis of the genotypes and growth traits is carried out, and finally it is determined that the amplified RBAT gene fragment can be used as a molecular marker related to tail fat of the sheep. The application can be used for selecting and reserving TT homozygous sheep into a core group, for reducing tail fat deposition of the sheep, and for increasing economic benefits.

The invention provides an application of a molecular marker related to a sheep tail fat deposition character in breeding. According to the invention, PCR amplification and sequence analysis are carried out on a sheep GDF10 gene, an A / T polymorphic site exists at the 614th site of an amplified fragment, an AQP primer pair is further used for detecting polymorphic sites of 795 Hu sheep and establishing a least square model, correlation analysis is carried out on genotypes and tail fat deposition traits, and the genotype and tail fat deposition traits are identified. Finally, it is determined that the amplified GDF10 gene segment can be used as the molecular marker related to the sheep tail fat deposition character. The molecular marker can be used for breeding low-tail fat type sheep in breeding by detecting the molecular marker, AT hybrid type sheep can be selectively reserved to enter a core group for breeding, tail fat deposition of the sheep can be reduced, and economic benefits can be increased.

Systems and methods for treating cellulite including an apparatus that applies or a method involving separating septa to eliminate or reduce the appearance of cellulite. In one approach, an interventional tool is placed between tissue layers to engage and treat septa connecting tissue layers between which fat deposits are contained.

This invention provides the application of a *Breago brevis* strain in the preparation of products that promote intramuscular fat deposition in livestock and poultry. The *Breago brevis* strain is *Breago brevis* JCM 32280. Under high-fiber dietary conditions, supplementation with *Breago brevis* JCM 32280 of this invention can efficiently degrade fiber to produce high concentrations of butyrate. Butyrate, as a key effector molecule, can directly bind to and activate PPARγ receptors in host cells, thereby upregulating the MOGAT2-mediated triglyceride synthesis pathway, significantly increasing body fat percentage in mammals and promoting intramuscular fat (marbling). Simultaneously, this strain can reshape the intestinal microecology, specifically increasing the abundance of beneficial intestinal lactobacilli and enhancing the intestinal mucus barrier, providing a safe and efficient microbial preparation strategy for improving the fat deposition capacity and meat flavor of livestock and poultry.

The invention relates to the technical field of poultry health assessment, in particular to a method for predicting and identifying the high fat deposition risk of the liver of a laying hen based on blood amino acid parameters. The method comprises the following steps: collecting a blood sample when the laying hen is in a metabolic state after absorption, detecting the total amino acid content and the alanine content in blood, and substituting blood parameters into a pre-established liver triglyceride prediction model to obtain the predicted liver triglyceride content, and comparing the prediction results to judge the high fat deposition risk of the liver of the laying hen. According to the method, the laying hens do not need to be slaughtered and sampled, the fat deposition state of the livers of the living laying hens can be rapidly evaluated, and the method is suitable for early screening and risk early warning of high fat deposition of the livers of the laying hens under the large-scale breeding condition.

The invention discloses application of a pig SOS1 gene in regulation and control of adipocyte differentiation, and relates to the technical field of biology. An overexpression system is constructed by exogenously introducing a swine SOS1 gene into 3T3-L1 precursor fat cells of a mouse, and the influence of the overexpression system on adipogenic differentiation of the cells is detected; researches find that the overexpression of the pig SOS1 gene significantly promotes the adipogenic differentiation of 3T3-L1 cells of mice, and improves the mRNA and protein expression levels of key adipogenic markers PPAR gamma, FABP4 and HSL. The invention provides a theoretical basis for improving the fat deposition character of the pig.

The invention discloses application of an Fn1-PPARbeta / delta signal channel related to a cardiac liver disease. The cardiac liver disease model is constructed according to the conditions that the liver development of young individuals is delayed due to heart injury and both adult and young individuals have serious fatty livers. In the model, the Fn1 protein level in the heart and blood is obviously increased compared with the normal level. Based on a zebra fish heart ablation means, after heart ablation injury, the heart specific knock-down Fn1 can lead to reduction of the Fn1 protein level in blood and alleviation of liver development retardation and fat deposition. Through the screening of transcriptomics, the PPARbeta / delta protein in the liver is found to be a potential downstream effect factor of Fn1. The liver specific overexpression PPARbeta / delta protein can significantly relieve abnormal phenotypes such as liver fat deposition caused by heart injury, and after the liver specific knock-down PPARbeta / delta protein, the protection effect of knock-down Fn1 on the liver disappears under the condition of heart injury. Therefore, the Fn1 protein and the PPARbeta / delta protein can be used as targets for preventing and treating the cardiac liver injury, and are used for preparing medicines for improving the cardiac liver injury, so that a new way is provided for treating the cardiac liver disease.

The application belongs to the technical field of poultry breeding, and discloses siRNA for targeted inhibition of chicken PLCD4 gene expression and application thereof; the siRNA comprises PLCD4-853, PLCD4-528 and PLCD4-1870; the siRNA for targeted inhibition of chicken PLCD4 gene expression can effectively reduce the expression of the chicken PLCD4 gene after being introduced into chicken primary subcutaneous adipocytes, and the inhibition efficiency is more than 50%, and the knockdown efficiency is very high; the siRNA can be used for identifying gene functions by specifically knocking down the expression of the chicken PLCD4 gene in vitro, and can be applied to genetic selection of high-quality broiler subcutaneous fat deposition as a molecular marker, and has great economic value and scientific research value.

The invention belongs to the technical field of poultry breeding, and discloses a siRNA for targeted inhibition of chicken FBXW7 expression and an application thereof; the siRNA comprises FBXW7-834; the siRNA capable of targeted inhibition of chicken FBXW7 gene expression can effectively reduce the expression of the chicken FBXW7 gene after being transferred into primary abdominal fat cells of chickens, with an inhibition efficiency of more than 50%, and a very high knockdown efficiency; the siRNA identifies the gene function by specifically knocking down the expression of the chicken FBXW7 gene in vitro, can be used as a molecular marker in the genetic selection of abdominal fat deposition in high-quality broilers, and has great economic value and scientific research value.